Scalper1 News
Specialty drugmaker Pernix Therapeutics (PTX) popped to its highest point in nearly four years Wednesday after it agreed to acquire a controversial pain medicine for up to $383.5 million. Late Tuesday, Pernix agreed to pay $100 million upfront in cash and stock for Zogenix’s (ZGNX) Zohydro ER franchise, which includes three long-acting versions of the popular pain drug hydrocodone. Pernix also agreed to a $12.5 million milestone payment if an Scalper1 News
Scalper1 News